Research programme: transplant rejection therapy - Borean Pharma
Alternative Names: IL-2 alpha receptor antagonist - Borean PharmaLatest Information Update: 09 Aug 2007
At a glance
- Originator Borean Pharma
- Class
- Mechanism of Action Interleukin 2 receptor antagonists; Interleukin-2 receptor alpha subunit antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection
Most Recent Events
- 09 Aug 2007 Discontinued - Preclinical for Transplant rejection in Denmark (unspecified route)
- 25 Feb 2004 Preclinical trials in Transplant rejection in Denmark (unspecified route)